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‘People here think that the Red Cross is taking blood out of the dead people when 
they come to prepare the burials in order to send it to Europe and make money out of 
it’ – Interview with a man from Macenta, Guinea. 
 
The urgent need to contain the Ebola epidemic has led to fast-tracked clinical 
treatment trials, including blood or plasma from Ebola survivors.1 However, blood 
sampling is associated with considerable fear and reticence throughout sub-Saharan 
Africa, including rumours of ‘blood stealing’.2 In the context of the convalescent blood 
trial, ‘blood’ has ambiguous meaning: while the blood of sick people should be 
avoided, the transfer of blood from previously infected people is a potential therapy. 
There are anecdotes that blood from Ebola survivors is being traded informally, 
suggesting it is already a valuable commodity. Meanwhile, rumors are circulating that 
Ebola patients in treatment centres are being injected with infected blood to hasten 
death.  
 
Such perceptions should not be dismissed as  ‘superstitions’ or ‘ignorance’ as they 
function as a means of understanding the cause of misfortune, framed in magico-
religious beliefs such as sorcery, the influence of ancestors or the will of God.3 
Furthermore, they reflect a historically forged mistrust towards certain institutions, 
reinforced by social inequality, conflict and a conviction that some people are rich 
and influential at the cost of the poor.4 For example, the epicentre of the Ebola 
epidemic was also the location of epidemics of sleeping sickness that were fought in 
colonial times with measures including forced internment in treatment camps.5 The 
legacy of these campaigns should be recognised when considering current 
suspicions about the Ebola response. 
 
In addition, ongoing stigmatization of Ebola survivors, who will donate blood for the 
treatment of Ebola cases, will be affected by the outcome of the trial. A positive result 
may foster the re-integration of survivors into their communities or, conversely, if 
convalescent blood treatment proves ineffective, donors may be suspected of 
causing more deaths. The post-trial follow up of participants therefore becomes an 
ethical requirement.  
 
Ebola trials must consider local perceptions of blood and other contextual factors. 
Unfortunately, despite anthropological insights, there has been insufficient 
opportunity for interdisciplinary research to investigate the impact of beliefs about 
blood on clinical trials and consequently little evidence on which to base 
recommendations for Ebola trials. While this approach is paramount for the fight 
against Ebola, many of the considerations discussed here have broad applicability.  
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